Prid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prid

What is Prid? An Overview

Property Description
Active Ingredient Progesterone (Micronised Progesterone)
Form Intravaginal Device
Pharmacological Class Progestogen (Sex Hormone)
Common Use Synchronization of Oestrus in Cattle
Origin Steroid Hormone (Natural or synthetic equivalent)

What is Prid and Its Pharmaceutical Classification?

The Prid product is accurately defined as a specialized Progesterone Releasing Intravaginal Device, used exclusively as a veterinary medicinal product in cattle (cows and heifers). The product's classification places it within the Pharmacological class of Progestogens, which are synthetic or naturally derived Sex Hormones. This device is explicitly not formulated or authorized for any human therapeutic application.

This specific device is a critical tool in coordinated planned breeding programs in livestock. This systemic approach is clinically recognized for its effectiveness in synchronizing ovarian cycles in heifers, simplifying herd management. This means the medicine aids in coordinating the fertile period across a group of animals for highly efficient breeding management.

Composition, Physical Form, and Differentiating Features

The active component in Prid is micronised progesterone, a single-component product that is chemically identical to the naturally occurring steroid hormone. A differentiating feature of the Prid system is its unique physical presentation as an Intravaginal Device, which typically utilizes a cylindrical stainless steel spiral coil coated with an elastomer. This structure ensures the slow, continuous, and highly controlled release of the hormone via the Intravaginal route.

The micronised progesterone is integrated into this inert physical structure, which serves as the total vaginal delivery system. This specific structural design allows for a defined and predictable hormonal release profile, making the device a reliable choice for achieving a controlled hormonal environment necessary for reproductive management.

The General Purpose of This Intravaginal Delivery System

The primary function relies on the principle of controlled hormonal delivery to establish a state of temporary reproductive quiescence. The consistent release of progesterone simulates the presence of a functional corpus luteum, creating a robust negative feedback loop that temporarily prevents the natural hormonal cascade required to initiate a new cycle.

The core purpose of the Prid delivery system is the establishment of this controlled hormonal plateau. Its subsequent, rapid removal causes a sudden and simultaneous drop in circulating progesterone levels. This abrupt hormonal withdrawal is the definitive signal that effectively triggers the coordinated onset of oestrus (heat) and subsequent ovulation across the entire treated group.

What side effects are possible with Prid?

Possible Side Effects and Safety Information

The officially documented safety profile for the Progesterone Releasing Intravaginal Device (Prid) is focused on the target species, cattle, and is structured around localized, temporary reactions as classified in government regulatory documents.


Officially Classified Adverse Reactions

The most frequently occurring adverse reactions are classified as Common in the official Summary of Product Characteristics (SmPC). These reactions are confined to the Reproductive System and Breast Disorders (Genital Tract) System-Organ-Class (SOC) and are associated with the physical presence of the device:

  • Vaginal discharge: Documented as ropy or cloudy vulvar secretions.
  • Mild local reaction: Inflammation of the vaginal wall, or vaginitis, which occurs during the seven-day treatment period.

Both the discharge and local inflammation are documented in regulatory sources as resolving rapidly and spontaneously after the device's removal, and are explicitly stated to not affect subsequent fertility at insemination or overall pregnancy rates.


Safety Constraints and Contraindications

The use of the device is subject to administration-agnostic safety boundaries detailed in official labeling:

  • Contraindications: Use is strictly prohibited in pregnant animals, sexually immature heifers, animals suffering from genital infections or pre-existing discharge, those with abnormal genital tracts, and animals in a poor nutritional state.
  • Post-Parturition Constraint: Treatment should not be initiated until at least 35 days have elapsed since previous calving.

Official labeling notes that the risk of overdosage is considered not possible due to the product’s design as a physical delivery system, and there are no known interactions with other medicinal products reported in the SmPC. The official withdrawal period for both meat and offal and milk is zero.

Overdose and Emergency Response

The official regulatory profile for the Prid Progesterone Releasing Intravaginal Device, a product used exclusively in cattle (cows and heifers), is structured around its unique fixed-dose delivery system. Official government prescribing information consistently classifies the concept of overdosage for this veterinary product as Not Applicable.

This specific determination stems directly from the device’s pharmaceutical form. The product is physically designed as a controlled-release device which restricts the total amount of progesterone available for systemic exposure at any given time. This intrinsic characteristic prevents the acute overexposure that would be required to precipitate a classical clinical overdose scenario. Because the product is not a conventional dosage form where a high quantity could be improperly administered, the overall systemic safety profile is dictated by the device's physical limitations.

Overdose Feature Official Regulatory Status
Documented Manifestations Not Applicable. No clinical signs or symptoms are listed in official documents.
Required Emergency Actions Not Applicable. No specific immediate actions or emergency procedures are mandated by regulatory authorities.
Antidote or Support Not Applicable. No supportive measures or specific antidotes are described in the regulatory labeling.

Consequently, the official regulatory documentation does not list any associated symptoms, clinical manifestations, physiological findings, or specific requirements for immediate medical help in the event of an overdose. The regulatory basis establishes that no urgent response or specific monitoring is required for an event that is officially deemed not possible under the approved conditions of use.

Therapeutic Uses of Prid

What Prid Treats: Main Uses and Benefits


The Prid intravaginal delivery system is a veterinary medicinal product used exclusively in cattle (cows and heifers) to manage and coordinate their reproductive cycles. Its core therapeutic purpose is applied in controlling the oestrus cycle and supporting efficiency in breeding operations.

Quick Fact: Relief for Scheduling Disruption

The system provides supportive relief for management during symptomatic phases by assisting with maintaining functional stability and may assist with reducing reliance on labor-intensive visual heat detection.


The device is commonly used for managing the clinical patterns of anoestrus (non-cycling status), suboestrus (difficult-to-detect heat signs), and the challenge of coordinating fertility across a group. This provides support for planned, efficient group breeding programs and Fixed-Time Artificial Insemination (FTAI), which generally helps improve the predictability of calving and overall herd management. The device is relevant for the supportive management and induction of cyclicity in these non-cycling animals, offering critical support in assisting with the re-establishment of reproductive function and contributing to easing the overall symptom load related to reproductive dysfunction.

Regulatory References

  1. Summary of Product Characteristics (SPC) via VMD (UK's Veterinary Medicines Directorate)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Prid Drawing Salve

This eligibility profile is based strictly on the official warnings and statements documented in the over-the-counter regulatory labeling.

Field Official Regulatory Statement
Populations for whom use is allowed Adults and children 6 years and over (must use externally as directed).
Populations for whom use is contraindicated No systemic contraindications are listed; exclusions apply to site and injury type.
Age-related eligibility rules Children under 6 years: Use is restricted and requires consultation with a physician before application.
Pregnancy and lactation eligibility status If pregnant or breastfeeding: Use is conditional and requires consultation with a health professional before use.
Eligibility-related restrictions Must not be used in eyes, mouth, or nose. Must not be used on deep puncture wounds, animal bites, or serious burns.

Eligibility-Context Constraints

The regulatory labeling dictates that Prid is for External Use Only. Use is absolutely prohibited on wounds categorized as deep (puncture wounds, bites, severe burns), as these injuries necessitate immediate professional medical assessment rather than self-treatment with this product. Consultations are explicitly required for the younger pediatric population and for those who are pregnant or breastfeeding, establishing the full scope of eligibility constraints.

What should I know about interactions with other medicines?

Prid Interactions with other medicines and products

Interaction Scope Official Regulatory Finding
Documented Adverse Interactions None known with other medicinal products, food, or substances.
Required Pharmacodynamic Agents Prostaglandin F2α or analogue; Gonadotropin Releasing Hormone (GnRH) or analogue; Equine Chorionic Gonadotrophin (eCG).
Timing-Based Rules Prostaglandin F2α or analogue must be administered by injection 24 hours prior to the removal of the device.

Interaction Classification and Profile

The regulatory profile for this product is defined by its function as one component of a larger, required therapeutic regimen. The official documentation formally states that there are no known adverse interactions that alter the clearance, metabolism, or exposure of the progesterone active substance when co-administered with other drugs outside the synchronization protocol. This includes a lack of documented interactions involving metabolic pathways or drug transporters.

The only interactions formally described are mandatory pharmacodynamic interactions essential for the device's approved use. The official protocols dictate that the product must be co-administered with specific hormones, such as Prostaglandin F2α or analogues. These protocols include mandatory timing-based rules, such as the requirement for the F2α injection to be administered 24 hours before the device is removed, which is a required condition for the interaction to be effective.

Mechanism of Action

The mechanism of action for Prid Salve is exclusively peripheral and operates through three distinct topical domains, driven primarily by Ichthammol and the occlusive base.

Localized Skin Barrier Modulation

The salve's occlusive base creates a moisture-trapping environment, facilitating the maceration of the stratum corneum. This physical action and an induced osmotic mechanism encourage the expulsion of surface irritants and trapped fluid, resulting in the modification of localized tissue pressure and fluid dynamics.

Peripheral Anti-Inflammatory Dampening

Ichthammol exerts a mild peripheral anti-inflammatory effect by interacting with local mediators released during acute irritation at the application site. This action modulates the early molecular steps of the inflammatory cascade, leading to the physiological consequences of reduced erythema and edema without systemic pathway interference.

Topical Antiseptic and Microbial Control

Ichthammol's antiseptic properties maintain a less favorable environment for the proliferation of surface skin flora. This non-specific chemical interaction aids in minimizing the local microbial burden, contributing to the local modulation of tissue repair dynamics and influencing subsequent tissue responses.

Dosage and Administration Information

The Prid intravaginal delivery system is a single-use veterinary medicine utilized exclusively in cattle (cows and heifers) for reproductive cycle control. Its administration follows a precisely defined protocol focused on the intravaginal route.


Administration Protocol and Dosage

The product is administered as a single device containing 1.55 g of micronised progesterone per animal. The device is placed intravaginally using a dedicated applicator, which requires pre-cleaning, disinfection, and lubrication with obstetrical lubricant as part of the preparation requirements. This procedural conditioning ensures correct delivery of the medicine. The device is intended to remain in place for a fixed duration of seven days. This specific timeframe is critical to the synchronization process, as its sudden removal at the end of the course triggers the desired hormonal response.


Population and Contextual Rules

Treatment is limited to cows and heifers and may be initiated a minimum of 35 days following parturition. Prid is used in lactating animals. Crucially, the device is not intended as a standalone treatment but must be utilized in combination with other hormonal injections (such as Prostaglandin F2α) to complete the full oestrus synchronization regimen. This combination treatment approach is fundamental to the system's use pattern. All handling, including insertion and removal by pulling the removal tail, requires the operator to wear protective gloves, a procedural condition for the application.

Recent Clinical Evidence

Prid: Recent Clinical Evidence

The following information summarizes findings from clinical trials and research studies involving Pridopidine (the active compound in Prid) to provide a descriptive overview of the evidence.


Overview of Clinical Research

Studies have explored the drug's influence on markers associated with the inflammatory response and the immune system. One trial examined whether the study intervention was associated with changes in overall quality of life measures. Separately, research has explored the drug's effect on measured outcomes for the frequency and severity of flare-ups.

The drug is one treatment option that has been the subject of several clinical trials evaluating its use in various adult patient populations.


Key Efficacy and Safety Findings

The primary, large-scale study reported that participants who received the study intervention showed a statistically significant difference in key disease markers compared to placebo at 12 weeks. However, this study did not meet its initial primary composite endpoint in the first 26 weeks, demonstrating that measured outcomes can vary by timepoint and specific variable.

Other studies have explored the clinical outcomes when the study intervention was used in combination with another treatment. One comparative study examined the difference in measured variables for pain and inflammation between the study intervention and another medication.

Safety data from clinical trials have been analyzed across various adult patient populations. The drug has been studied alongside other treatment options that are commonly prescribed first-line. Studies have not yet established whether the drug prevents disease progression. Clinical trials reported various side effects, and the severity of these effects was documented by investigators, with the most common being insomnia, diarrhea, nausea, and dizziness.

Frequently Asked Questions (FAQ)

Common questions about Prid (FAQ)

Q: Is Prid generally considered a homeopathic remedy or a standard topical ointment?

Prid is officially designated as a homeopathic medicine. This classification is due to its active ingredients being prepared and listed according to the Homeopathic Pharmacopoeia of the United States (HPUS). The product's homeopathic nature means its composition, manufacturing, and indications are regulated under this system.

Q: Are the active ingredients in Prid regulated or recognized by the FDA?

Yes, the active ingredients in the product are recognized and governed by the Homeopathic Pharmacopoeia of the United States (HPUS). This HPUS recognition serves as the basis for the product's regulatory pathway as an over-the-counter medicine.

Q: Is Prid available for purchase without a prescription?

According to regulatory documentation, Prid is classified as an Over-The-Counter (OTC) product. This status means the product is legally available for purchase without requiring a prescription from a healthcare provider.

Q: Is Prid drawing salve suitable for all types of insect bites and stings?

Official product information states the salve is indicated for temporary topical relief of pain and irritation associated with insect bites. The scope of relief is defined by the product label, which includes easing pain and helping to heal the affected skin from minor irritations.

Q: Is it appropriate to use Prid on acne blemishes that are not deep or cystic?

The product is officially indicated for temporary topical relief of pain and irritation associated with minor skin eruptions. This general category covers a range of minor surface irritations that are not classified as deep or serious wounds.

Q: Can Prid be used to help remove small glass shards, or is it only for splinters and thorns?

The salve is primarily indicated to help draw out irritations like splinters and thorns from under the skin. Its overall intended function is to encourage the expulsion of foreign material and surface irritants from the affected area.

Q: What specific types of boils or abscesses is Prid not recommended for?

Official product warnings advise against using the product on deep puncture wounds or serious burns. The label also states that the product should be discontinued, and professional attention sought, if symptoms worsen or if a fever develops.

Q: What is the purpose of the Arnica Montana component in the product?

The active ingredient Arnica Montana is included in the formula with the purpose, as defined in the HPUS, of easing pain and swelling. This contributes to the product's function of providing temporary topical relief at the site of the irritation.

Q: Is the ingredient Silicea in the salve intended to help with the extraction process?

The purpose of the active ingredient Silicea is defined in the HPUS as helping to draw out splinters, thorns, and ingrown hairs from under the skin. This specific function aligns with the product's designation as a drawing salve.

Q: How do the multiple active ingredients in Prid interact with the skin?

The combination of active ingredients is formulated to provide multiple topical effects on the skin. These include easing pain and swelling, helping to heal the skin, and relieving itching and localized irritation at the application site.

Q: Does Prid contain any animal-derived ingredients?

The official list of inactive ingredients for the salve includes beeswax. Beeswax is an animal-derived component, confirming the presence of at least one non-synthetic material in the product.

Q: Does Prid contain any common topical allergens like lanolin or parabens?

Official labeling lists inactive ingredients such as petrolatum, beeswax, and wood rosin. While some modern formulations are officially labeled as Paraben Free, individuals with specific allergen concerns may wish to review the entire inactive ingredient list.

Q: What are the main inactive ingredients that give Prid its salve consistency?

The salve consistency is provided by the inactive ingredients, which officially include Petrolatum, Beeswax, and Stearyl Alcohol. These components form the occlusive base that helps create the moisture-trapping environment on the skin.

Q: What are the most common reported side effects associated with the use of Prid?

The product labeling does not list specific adverse effects but advises that the product should be discontinued and a doctor consulted if local irritation, pain, swelling, or redness persists or worsens. These local changes are listed as reasons for discontinuation.

Q: Is it possible to develop an allergic reaction to the botanical ingredients in Prid?

Official warnings indicate that the product should be discontinued and medical consultation sought if irritation, pain, swelling, or redness persists or worsens. This instruction covers the local symptoms that could indicate an allergic or sensitivity reaction to the product’s components.

Q: What are the established warning signs that signal Prid use should be discontinued?

Official warnings state that the product should be discontinued if symptoms persist for more than seven days or worsen. Discontinuation is also advised if irritation, pain, swelling, or redness persists or worsens at the application site.

Q: What should a user do if the skin irritation seems to worsen after applying Prid?

If the skin irritation seems to worsen after applying the product, regulatory warnings state that the product should be discontinued. At this point, the individual is advised to seek consultation with a healthcare professional.

Q: What is the procedure if a small amount of Prid is accidentally swallowed?

The warning label advises seeking professional assistance immediately, typically by contacting a poison control center. This instruction is necessary due to the possibility of accidental ingestion.

Q: What is the recommended typical duration of use for Prid on a small skin eruption or boil?

Regulatory directions define the maximum treatment frequency as twice daily until irritation subsides. Critically, the warning states that use must be stopped if symptoms persist for more than seven days, establishing a maximum duration for self-treatment.

Q: Is there a maximum number of times per day that Prid can be safely reapplied?

Regulatory directions define the maximum frequency of application as twice daily until the irritation subsides. Once irritation subsides, the frequency may be reduced to once daily for several days.

Q: What specific symptom persistence should prompt a user to contact a healthcare professional?

Regulatory warnings advise consultation with a healthcare professional if symptoms persist for more than seven days or if they worsen. Furthermore, the warning explicitly states that professional medical attention should be sought if a fever develops.

Q: Is it always necessary to cover the area with a bandage or gauze after applying Prid?

Regulatory directions define the application process as requiring the affected area to be covered with a clean bandage or gauze after application. This covering should remain in place, as per the twice-daily application schedule, until the irritation subsides.

Q: What are the specific guidelines for applying Prid to a superficial cut or scrape?

Regulatory directions specify that the affected area must first be washed and dried thoroughly. Following this, the product should be applied and covered with a clean bandage or gauze.

Q: What is the proper method for cleaning the skin before the application of Prid?

Regulatory directions specify that the affected area should be washed with warm water and dried as a required step before the application of the product. Proper preparation of the area is outlined as the first step in the application process.

Q: Is it generally acceptable to leave the application of Prid on the skin overnight?

Official directions recommend applying the product twice daily on the affected area. This twice-daily application schedule implies that the product is intended to be worn for extended periods, including overnight, between applications.

Q: Is Prid meant only for temporary relief, or is it intended for continuous use?

The product is officially indicated only for temporary topical relief of pain and irritation. It is not intended for continuous use, as the label directs users to stop use if symptoms persist beyond seven days.

Q: Can Prid be used for minor irritations on sensitive areas like the face?

The official labeling lists specific body areas that are prohibited from use, including the eyes, mouth, and nose. These warnings establish clear boundaries for external use, avoiding delicate internal membranes and sensitive structures.

Q: Can Prid be stored in different temperature conditions without affecting its effectiveness?

The official regulatory label instructs that the product should be kept in a cool, dry place. Following this storage direction is intended to help maintain the product's consistency and stability.

How should Prid be stored and disposed of?

Official Storage and Disposal Instructions

The storage and disposal of the Prid intravaginal device are strictly defined in regulatory documents to ensure product stability and safety. The product does not require special storage conditions, though some labeling specifies storing it in a cool, dry place below 25 C and always in its original sachet.

Condition Regulatory Requirement
Unopened Shelf-Life 3 to 4 years
Post-Opening Stability 6 months after the immediate sachet is first opened
Child Safety Keep out of the sight and reach of children
Operator Handling Must wear gloves during handling (insertion and removal)

The device is for single use only. Any unused devices or waste material must be disposed of in accordance with local requirements for veterinary medicinal products. The mandatory handling instructions require the operator to wear gloves and wash hands after use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prid found in:

A-Z Index: